Clinical Trials Logo

Filter by:
NCT ID: NCT04861259 Recruiting - Clinical trials for Atypical Hemolytic Uremic Syndrome

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

COMMUTE-a
Start date: October 22, 2021
Phase: Phase 3
Study type: Interventional

This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

NCT ID: NCT04860661 Recruiting - Clinical trials for Postpartum Depression

Esketamine on Postpartum Depression in Cesarean Section Women

EKET
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

This study was to explore the preventive effect of esketamine on postpartum depression in cesarean section, and to evaluate the safety of the drug

NCT ID: NCT04860154 Recruiting - Clinical trials for Cholangiocarcinoma Non-resectable

Photodynamic Therapy for Cholangiocarcinoma

Start date: April 17, 2021
Phase: N/A
Study type: Interventional

Comparison of the bile duct patency with photodynamic therapy (PDT) and regular Endoscopic Retrograde Cholangiopancreatography(ERCP) stents in unresectable cholangiocarcinoma.

NCT ID: NCT04859959 Recruiting - Adrenal Mass Clinical Trials

Gallium-68 Labeled Pentixafor PET/CT in Adrenal Masses

Start date: July 1, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The CXC chemokine receptor type 4 (CXCR4), which is a G protein-coupled receptor expressed on the surface of the cell membrane, contributes to the development and progression of malignancies and functional endocrine disorders. CXCR4 expression has been reported to be upregulated in aldosterone-producing adenomas and cortisol-producing adenomas; however, its expression is almost negligible in non-functioning adrenal adenomas. Besides, CXCR4 is also hardly expressed by the tumor cells in paragangliomas. 68Ga-pentixafor, a CXCR4-specific PET tracer, may therefore be effective for the evaluation of the functional lateralization of adrenal lesion and identification of functional adrenocortical adenomas. In this pilot study, we aimed to develop 68Ga-pentixafor PET/CT as a noninvasive test for the recognition of functional adrenocortical lesions and to help guide the management of patients with suspicious adrenal masses.

NCT ID: NCT04859751 Recruiting - Clinical trials for Non-Muscle Invasive Bladder Cancer

Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer

Start date: March 23, 2021
Phase: Phase 3
Study type: Interventional

Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. VB4-845 injection is an experimental agent that may provide an alternative to cystectomy

NCT ID: NCT04859712 Recruiting - Clinical trials for Lumbar Disc Herniation

A Diagnostic Test of Abnormal Sound Waves in Modern Pulsology of Lumbar Disc Herniation

Start date: April 9, 2021
Phase:
Study type: Observational

The purpose of this study is to use the " Pulse Detection System of Sound Waves " to collect the pulse information of recruited subjects, and to extract characteristic pulse information by multi-scale entropy, Fourier transform, Hilbert yellow transform, spectrum analysis, wavelet analysis and other methods. Evaluate the specificity, sensitivity, positive likelihood ratio and negative likelihood ratio of the "Pulse Detection System of Sound Waves" in the diagnosis of lumbar disc herniation.

NCT ID: NCT04859634 Recruiting - Clinical trials for Artificial Intelligence

Real-time Artificial Intelligence System for Detecting Multiple Ocular Fundus Lesions by Ultra-widefield Fundus Imaging

Start date: November 1, 2020
Phase:
Study type: Observational

This prospective multicenter study will evaluate the efficacy of a real-time artificial intelligence system for detecting multiple ocular fundus lesions by ultra-widefield fundus imaging in real-world settings.

NCT ID: NCT04859621 Recruiting - Clinical trials for Recurrent Urinary Tract Infection

Phase II Clinical Trial of Vitamin D3 for Reducing Recurrence of Recurrent Lower Urinary Tract Infections

Start date: May 8, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study was to initially evaluate the optimal dose, efficacy, and safety of vitamin D3 for reducing recurrence of recurrent urinary tract infections (rUTIs).

NCT ID: NCT04859569 Recruiting - Clinical trials for Bone Metastases From Solid Tumors

Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors

Start date: April 30, 2021
Phase: Phase 3
Study type: Interventional

This is a multicenter,randomized, double-blind, active-controlled, parallel-group study comparing efficacy and safety of LY01011 (recombinant anti-RANKL human monoclonal antibody injection) and Xgeva® in patients with bone metastases from solid tumors.

NCT ID: NCT04859504 Recruiting - Schizophrenia Clinical Trials

Developing Dual-channel Transcranial Alternating Current Stimulations Targeting Negative Symptoms in Schizophrenia

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Negative symptoms are core symptoms in schizophrenia which play an important role in clinical outcomes and impede patients to return to society. Anti-psychotic medicines have shown limited effect in improving negative symptoms and cognitive functioning, whereas non-invasive neuromodulations, i.e. , transcranial alternating current stimulation (tACS), have shown promising potentials. Recently new evidence of brain structural and functional alterations has been provided by neuroimaging studies. Brady RO et al. found cerebellar-prefrontal network connectivity was related to negative symptoms in schizophrenia. It provides clues for developing a new tACS protocol targeting improving negative symptoms, in which dual-channel high-density alternating current stimulations were delivered over both the right dorsolateral prefrontal cortex and cerebellum simultaneously.